While results with ICIs for the treatment of patients with BCs have thus far been disappointing, including a reported 0% ORR with the combination of nivolumab and ipilimumab in the Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors (DART) trial among patients with low or intermediate grade non‐pancreatic NETs, there are two ongoing single‐arm trials combining nivolumab with standard of care therapy.75 The gene discussed is CTLA4; the disease is pancreatic neuroendocrine tumor.